Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Influenza vaccine GSK2340272A · 1 trial · 1 indication
Titers are presented as geometric mean titers (GMTs). The flu strain assessed was Flu A/CAL/7/09. The reference seropositivity cut-off value was greater than or equal to (≥) 1:10.
| Arm | Type | Description |
|---|---|---|
| GSK2340272A GROUP | EXPERIMENTAL | Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21. |
| GSK2340274A GROUP | EXPERIMENTAL | Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340274A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21. |
| Name | Type | Description |
|---|---|---|
| Influenza vaccine GSK2340272A | BIOLOGICAL | Two intramuscular injections at Day 0 and Day 21 |
| Influenza vaccine GSK2340274A | BIOLOGICAL | Two intramuscular injections at Day 0 and Day 21 |
Inclusion Criteria: * Male or female aged 18 to 60 years inclusive, at the time of the first vaccination. * Subjects who the investigator believes that they can and will comply with the requirements of the protocol. * Written informed consent obtained from the subject. * Satisfactory baseline medic...
Influenza vaccine GSK2340272A is an investigational vaccine being studied for the prevention of influenza, commonly known as the flu. It is designed to elicit an immune response against the H1N1 influenza strain. The vaccine is currently in Phase 3 clinical development and has not yet been approved by regulatory authorities.
Influenza vaccine GSK2340272A targets the H1N1 influenza virus strain. As a vaccine, it works by presenting components of the virus to the immune system to stimulate the production of antibodies, which can provide protection against subsequent infection with the H1N1 strain.
Influenza vaccine GSK2340272A is being developed by GSK plc, a global biopharmaceutical company. GSK plc is publicly traded under the ticker symbol GSK on major stock exchanges. The company is conducting clinical trials to evaluate the vaccine's safety and efficacy.
Influenza vaccine GSK2340272A is in Phase 3 clinical development. This phase involves large-scale studies to confirm the vaccine's effectiveness and monitor for adverse reactions in a larger population. The vaccine is still investigational and has not received regulatory approval for public use.
Influenza vaccine GSK2340272A has been studied in one completed Phase 3 clinical trial, identified as NCT00979407. This randomized, double-blind, controlled study enrolled 336 healthy adult participants in France and Germany to evaluate the immunological equivalence of the vaccine against H1N1 influenza.
Influenza vaccine GSK2340272A is a specific investigational vaccine developed by GSK plc. It is not identified as being the same as other marketed influenza vaccines. The vaccine is being studied for its ability to provide immunity against the H1N1 strain, but it is not yet approved for use.